Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for media industry professionals · Friday, March 29, 2024 · 699,712,494 Articles · 3+ Million Readers

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In CV Sciences, Inc. (Other OTC: CVSI) To Contact The Firm

STEVENSON, Md., Oct. 15, 2018 (GLOBE NEWSWIRE) -- STEVENSON, MD - The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of purchasers of CV Sciences, Inc. (Other OTC: CVSI) (“CV Sciences” or the “Company”) securities during the period between June 19, 2017 and August 20, 2018, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until October 23, 2018 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in CV Sciences securities during the Class Period.  Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that its Patent #15/426,617 received a non-final rejection from the US Patent Trademark Office (“USPTO”) on April 27, 2017 and a final rejection from the USPTO on December 14, 2017.

According to the complaint, following an August 20, 2018 report exposing the Defendant’s failure to disclose the final rejection of its Patent on December 14, 2017 and the mailed notice of final rejection on December 20, 2017, the value of CV Sciences shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in CV Sciences securities purchased on or after June 19, 2017 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.

CONTACT:  Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
hoffman@browerpiven.com

Powered by EIN News
Distribution channels: Consumer Goods, Law


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release